S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

BeyondSpring (NASDAQ:BYSI) Stock Rating Lowered by Zacks Investment Research

Last updated on Wednesday, January 13, 2021 | 2021 MarketBeat

BeyondSpring (NASDAQ:BYSI) was downgraded by Zacks Investment Research from a "buy" rating to a "hold" rating in a research note issued on Wednesday, Zacks.com reports.

According to Zacks, "BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. "

Other equities analysts also recently issued reports about the company. BidaskClub upgraded BeyondSpring from a "sell" rating to a "hold" rating in a research note on Thursday, December 17th. ValuEngine upgraded BeyondSpring from a "hold" rating to a "buy" rating in a research note on Friday, November 20th. Bank of America began coverage on BeyondSpring in a report on Monday. They set a "buy" rating and a $25.00 price target on the stock. HC Wainwright cut their price target on BeyondSpring from $46.00 to $43.00 and set a "buy" rating on the stock in a report on Tuesday, November 24th. Finally, Evercore ISI began coverage on BeyondSpring in a report on Monday, December 28th. They set an "outperform" rating and a $30.00 price target on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has an average rating of "Buy" and an average target price of $27.40.

BYSI stock traded down $0.09 during midday trading on Wednesday, reaching $12.95. The company had a trading volume of 423,599 shares, compared to its average volume of 331,175. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average price of $11.46 and a 200 day moving average price of $13.08. BeyondSpring has a fifty-two week low of $9.38 and a fifty-two week high of $21.50. The firm has a market capitalization of $395.18 million, a PE ratio of -6.35 and a beta of 0.60.

BeyondSpring (NASDAQ:BYSI) last issued its earnings results on Monday, November 16th. The company reported ($0.48) EPS for the quarter, beating the Zacks' consensus estimate of ($0.54) by $0.06. Research analysts predict that BeyondSpring will post -1.99 EPS for the current year.

Hedge funds have recently modified their holdings of the company. California Public Employees Retirement System acquired a new position in BeyondSpring during the second quarter valued at $413,000. Bank of New York Mellon Corp boosted its position in BeyondSpring by 7.5% during the second quarter. Bank of New York Mellon Corp now owns 31,354 shares of the company's stock valued at $473,000 after purchasing an additional 2,201 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in BeyondSpring by 7.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 29,211 shares of the company's stock valued at $441,000 after purchasing an additional 1,906 shares during the last quarter. Nuveen Asset Management LLC acquired a new stake in BeyondSpring during the second quarter valued at $503,000. Finally, BNP Paribas Arbitrage SA boosted its position in BeyondSpring by 506.9% during the third quarter. BNP Paribas Arbitrage SA now owns 3,344 shares of the company's stock valued at $45,000 after purchasing an additional 2,793 shares during the last quarter. Institutional investors and hedge funds own 7.10% of the company's stock.

About BeyondSpring

BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia.

Featured Story: How Investors Use a Balance Sheet

Get a free copy of the Zacks research report on BeyondSpring (BYSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BeyondSpring (NASDAQ:BYSI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


7 Entertainment Stocks That Are Still Delighting Investors

2020 has created a real-life movie script that many production companies could have only dreamed of. But that dream has been a nightmare for many of the world’s leading entertainment stocks. Movie theaters and live entertainment venues remain shut down. The words “pent-up demand” have never resonated more. Consumers are desperate for ways to be entertained.

That may make it an odd time to consider looking at entertainment stocks. But that would be a mistake. In fact, some entertainment stocks have been among the biggest pandemic winners. This is a trend that is likely to continue as the holidays arrive. The phrase “home for the holidays” is likely to have a new meaning this year. That means consumers will still be looking for ways to be entertained. And now is the time for you to prepare your portfolio for that move.

To be clear, the novel coronavirus was not due to poor management from any company. And you can bet that in the future, many companies will leave some room in their balance sheet for future “acts of God.” But in the meantime, some entertainment stocks have been pandemic winners. And that means they will likely continue to be winners as long as the pandemic lingers.

View the "7 Entertainment Stocks That Are Still Delighting Investors".

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.